CEP95

Across TCGA pan-cancer cohorts, CEP95 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEP95 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CEP95 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP95 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, KIRP, and UCEC are the cancer types where CEP95 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.300	0.924	<.001	36	view →
KIRP	OS	Median	All	0.176	0.885	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.892	0.301	.009	24	view →
BLCA	OS	Median	IV	0.120	0.599	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CEP95–BRCA (OS)

Open the BRCA breakdown →